A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua

O. Sjaastad, F. Antonaci

Research output: Contribution to journalArticle

Abstract

Piroxicam beta-cyclodextrin has recently been observed to be equal to, or even possibly to be superior to, indomethacin (mainly with regard to side effects) in a single case of hemicrania continua. Piroxicam beta- cyclodextrin, 20 to 40 mg per day, was, accordingly, tried in six patients with chronic paroxysmal hemicrania and six patients with hemicrania continua with a previously proven response to indomethacin. The study was conducted over a period of 3 weeks and in an open fashion. A placebo effect is considered to be negligible in these disorders. In such a comparison, piroxicam beta-cyclodextrin seemed inferior to indomethacin, in particular in chronic paroxysmal hemicrania.

Original languageEnglish
Pages (from-to)549-550
Number of pages2
JournalHeadache
Volume35
Issue number9
DOIs
Publication statusPublished - 1995

Keywords

  • chronic paroxysmal hemicrania
  • hemicrania continua
  • piroxicam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua'. Together they form a unique fingerprint.

  • Cite this